Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Finished Goods: 2016-2024

Historic Finished Goods for Heron Therapeutics (HRTX) over the last 9 years, with Dec 2024 value amounting to $6.2 million.

  • Heron Therapeutics' Finished Goods rose 60.79% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 60.79%. This contributed to the annual value of $6.2 million for FY2024, which is 37.11% down from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Finished Goods is $6.2 million, which was down 37.11% from $9.9 million recorded in FY2023.
  • Heron Therapeutics' Finished Goods' 5-year high stood at $18.7 million during FY2022, with a 5-year trough of $6.2 million in FY2024.
  • In the last 3 years, Heron Therapeutics' Finished Goods had a median value of $9.9 million in 2023 and averaged $11.6 million.
  • Per our database at Business Quant, Heron Therapeutics' Finished Goods crashed by 61.07% in 2021 and then skyrocketed by 199.22% in 2022.
  • Over the past 5 years, Heron Therapeutics' Finished Goods (Yearly) stood at $16.1 million in 2020, then slumped by 61.07% to $6.3 million in 2021, then surged by 199.22% to $18.7 million in 2022, then plummeted by 47.00% to $9.9 million in 2023, then slumped by 37.11% to $6.2 million in 2024.